Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
about
Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cellsNuclear actin and actin-binding proteins in the regulation of transcription and gene expressionSelective androgen receptor modulators in preclinical and clinical developmentAndrogen Receptor Structure, Function and Biology: From Bench to BedsideDichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer CellsSki-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription.Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancerSIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.Disruption of nongenomic testosterone signaling in a model of spinal and bulbar muscular atrophy.Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell linesInhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancerDevelopment of selective androgen receptor modulators (SARMs).FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.Hormone depletion-insensitivity of prostate cancer cells is supported by the AR without binding to classical response elements.Constitutive activity of the androgen receptor.CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor.The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancerPosttranslational modification of the androgen receptor in prostate cancer.Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.Pathogenesis of prostate cancer and hormone refractory prostate cancer.Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.Androgen receptor gene rearrangements: new perspectives on prostate cancer progressionNew insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer.Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells.Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanismsPersistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.Androgen receptor abnormalities in castration-recurrent prostate cancer.Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.
P2860
Q21132994-784417D6-4897-433E-9F8F-38DF6F9E81AAQ24608984-7BA06451-C5A0-4384-9BBE-6A8A5B4FEAA9Q24645579-5672FB98-2C16-4401-A210-EBCDA0570F57Q26750866-200ADBF9-9F83-4DC8-8380-4F9A85FCCC42Q26795738-A64CBEAD-9677-4B17-9F00-4B63906DB876Q28910351-15529091-BA3A-4FA4-87AD-D3AE64774D83Q30440162-361588E9-BCDE-414F-8BC5-921D8A3DDA3EQ33302103-6CBEEF25-126C-4436-B8DA-7AC6EA549938Q33574512-EFC20DBA-1D97-4E07-8BCB-0CD25ACA34BEQ33636403-07B0D85A-ABDE-444F-8F1F-D3E395A0EE09Q33988757-0E9DAA28-8DDA-46DF-A66E-33A5A4415938Q34043113-F08EFB51-162B-4365-99DA-EDDF07B76B9FQ34462138-D133B4A8-AFEC-4F21-8431-F9DD5A7FAEA3Q34558010-F98D8EC2-6289-4496-BE4D-FEE9B42E05E8Q34580343-9541EB36-2379-4689-B561-652BCD7E1CB7Q34712118-3E0D942B-2A81-4FB4-8553-EFDFFEF1890BQ34775572-94A06A6D-FD4F-4EED-A9CC-BA098D7D0A7DQ34786431-E89F9B10-DA46-469E-9AD7-8472BDF79259Q36003940-6FC10D91-BA9F-444F-9A35-9E8E77EEAF7FQ36315288-088E7F5D-B75E-4B71-BFC0-0C49B6489EA0Q36359489-A179D49D-998C-426A-B18D-E5F8931A3F4BQ36640426-97961F4B-49E0-43A2-B958-6890D96FEB8AQ36777961-4EF3ACCC-306C-44EC-A4E4-1E5290E0BF2BQ37092022-7DCB5502-0D70-49F6-A243-1A0FFAF06045Q37145531-3F6CCBE9-6A77-403A-873D-BE704A12F5EBQ37325266-E796CA02-548D-43E7-9260-141731B10FA5Q37367858-3C2B1C72-A453-4D74-952A-F1AB2A9A3942Q37560428-836B056F-5D24-43C3-9D9B-459FC9C8D46EQ37579070-7CD4CF24-425E-4BE2-A485-DB41B87AE96BQ37691775-A3D2AEFC-0E95-4EC8-9C81-98EFA4FD57FDQ37705831-90EA2321-953F-45C5-AF26-43C04A897021Q38076345-DAD3B300-1592-4632-BEFE-9255BB58E8B1Q38081525-D57FCD6B-BB21-427F-9ECE-A4B790473530Q38745981-6596D3C5-54A5-4281-B877-8AF799B7F55BQ38799717-DDD43C31-5C2C-4885-9F7D-307A5FA8C255Q39139830-92DF87D9-A67C-4E76-A24F-1EC6B4D314A4Q39195907-B6E22070-DA2A-4283-B123-61432443AE17Q39270073-ADEB62CC-000B-4ACA-8BE9-4075D16B0BBFQ39507379-DA668831-1050-4E1C-BD0F-814B425F0693Q39605639-0339CC50-64DE-4C29-985E-6CBEEC0C0FD0
P2860
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Ligand-independent androgen re ...... ractory prostate cancer cells.
@en
type
label
Ligand-independent androgen re ...... ractory prostate cancer cells.
@en
prefLabel
Ligand-independent androgen re ...... ractory prostate cancer cells.
@en
P2860
P356
P1476
Ligand-independent androgen re ...... ractory prostate cancer cells.
@en
P2093
Donald J Tindall
Scott M Dehm
P2860
P304
27882-27893
P356
10.1074/JBC.M605002200
P407
P577
2006-07-25T00:00:00Z